

Annual report on the remuneration of the management of Zentiva S.A. (the "Company")

The Company's Board of Directors (the "**Board of Directors**") has drawn up this annual report on the remuneration of the Company's directors (the "**Remuneration Report**"), which includes the remuneration and other benefits granted to the Company's directors during the financial year ended on 31 December 2021, in accordance with the remuneration policy of the Company's directors.

The Remuneration Report was submitted to the advisory vote of the ordinary general meeting of the Company's shareholders (the "**OGMS**") held on 28 April 2022, will be published on the Company's website at <u>www.zentiva.ro</u> and will remain publicly available for a period of 10 years from its publication, in accordance with the applicable legal provisions.

The Remuneration Report provides an overview of the remunerations, including all benefits, regardless of their form, which are granted or due during the last financial year to directors individually, including the newly appointed and former directors, in accordance with the Remuneration Policy.

	TotalgrossRemuneration(brokendownby components)	Relative proportion of the fixed remuneratio n	Relative proportion of the variable remuneration (performance bonus)	Other benefits obtained	Remuneration received from any Romanian entity which belongs to the same group and is controlled by/affiliated to the Company
Simona Cocoș – executive member and general manager	RON 1,010,470 (of which a fixed component of RON 804,914 and a variable component of RON 205,556)	80%	20%	 private healthcare subscription in the amount of RON 609 per year; benefits offered through the platform my.benefitonline.ro, in the amount of RON 1,000 per year; life and health insurance up to the limit of RON 667 per year. 	 RON 156,247 broken down as follows: a. RON 77,965 – total remuneration received from Labormed Pharma Trading S.R.L., representing only the fixed component (variable component – N/A); b. RON 78,282 – total remuneration received from Labormed-Pharma S.A., representing only the fixed component (variable component – N/A).
Margareta Tanase – executive member	RON 890,239 (of which a fixed component of	76%	24%	 private healthcare subscription in the amount of RON 609 per year; benefits offered through the 	RON 62,881 - total remuneration received from Labormed-

A. Remuneration structure of the Company's directors for the year 2021:

	RON 672,966 and a variable component of RON 217,273)			 platform my.benefitonline.ro, in the amount of RON 1,000 per year; life and health insurance up to the limit of RON 667 per year. 	Pharma S.A., representing only the fixed component (variable component – N/A).
Nicholas Robert Haggar – non- executive member (mandate valid until 18 August 2021)	N/A	N/A	N/A	N/A	N/A
Kevin Joseph Clifford – non- executive member (mandate valid as of 19 August 2021)	N/A	N/A	N/A	N/A	N/A
Kenneth Lynard – non-executive member	N/A	N/A	N/A	N/A	N/A
Marchand Francois Noel – independent non- executive member	RON 54,000 (of which a fixed component of RON 54,000 and a variable component of RON 0)	100%	0%	N/A	N/A

B. Comparative information on the modification of the remuneration and on the Company's performance

Annual modification	Financial year 2021 compared to financial year 2020	e e	Financial year 2019 compared to financial year 2018	Financial year 2018comparedtofinancial year 2017	Financial year 2017 compared to financial year 2016		
Directors remuneration							
Simona Cocoș – executive member and general manager	A 3% increase, with the "meets expectations" rating awarded in the year-end performance review;	"meets expectations"	A 4.5% increase, with the "meets expectations" rating awarded in the year- end performance review;	Non-remunerated mandate until August 2018	Non-remunerated mandate		
Margareta Tanase – executive member	A 8% increase, with the "meets expectations" rating awarded in the year-end performance review;	"meets expectations"	A 4.5% increase, with the "meets expectations" rating awarded in the year- end performance review;	Non-remunerated mandate until August 2018	Non-remunerated mandate		
Nicholas Robert Haggar – non- executive member (mandate valid until 18 August 2021)	Non-remunerated mandate until termination of mandate on 18 August 2021	Non-remunerated mandate	Non-remunerated mandate starting from December 2019	N/A	N/A		
Kevin Joseph Clifford – non- executive member (mandate valid as of 19 August 2021)	Non-remunerated mandate starting from 19 August 2021	N/A	N/A	N/A	N/A		
Kenneth Lynard – non-executive member	Non-remunerated mandate	Non-remunerated mandate	Non-remunerated mandate starting from October 2019	N/A	N/A		
Marchand Francois	0%	0%	0%	0%	0%		

Noel – independent						
non-executive						
member						
Company's performance						
Net profit	61.1% increase	40% increase	83% decrease	194% increase	22% increase	
EBITDA	60.6% increase	35% increase	80% decrease	153% increase	23% increase	
Average remuneration based on the full-time equivalent of the Company's employees						
Company's	A 4% increase as per	A 5% increase as per	A 4.5% increase as per	A 3.3% increase as	A 2.8% increase as	
employees	the Collective Labour	the Collective Labour	the Collective Labour	per the Collective	per the Collective	
	Agreement for 2021-	Agreement for 2020-	Agreement for 2019-	Labour Agreement for	Labour Agreement	
	2023	2021	2020	2018-2019	for 2017-2018	

The Company's directors are not included in any stock option plan granted or offered by the Company.

Annual modification of the remuneration

The increase in the fixed or variable remuneration will apply from 01.03.2022.

The value of the salary increase percentage applied to the fixed remuneration will vary for each director based on two criteria: the professional performance of the previous year and harmonisation with the labour market level.